Direxion Daily MSCI South Korea Bull 3X ETF (KORU)
KORU: The Korean Paradox: Record Profits, Prices At Their Lows
The Direxion Daily MSCI South Korea Bull 3X ETF (KORU) has fallen 73% from its highs while the KOSPI dropped 38%, even though SK Hynix's operating profit grew 500% in the same period. The KOSPI's forward P/E fell to 4.5x and its earning yield rose to 22%, driven mainly by forced margin call liquidations rather than weaker earnings. FLKR's daily RSI has already shown a V-shaped recovery near the 30 level, signaling renewed demand interest despite KORU's 3x leverage risks.
KORU Medical Systems Q2 Earnings Call Highlights
KORU Medical Systems NASDAQ: KRMD reported second-quarter revenue of $12 million, up 18% from a year earlier, as domestic patient starts, market-share gains and international demand supported growth. The company also said it achieved positive net income for the first time since 2019 and raised its full-year gross-margin outlook, while narrowing revenue guidance because certain international prefilled-syringe market launches are taking longer to develop than expected.
KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2026. The Company also updated guidance for the full year 2026. Second Quarter 2026 and Recent Highlights Net revenues grew 18% over the p.
KORU: Why Bearish South Korea Is The Play Into The Fall
I have a sell rating on Direxion Daily MSCI South Korea Bull 3X ETF due to technical weakness and high volatility. KORU is closely tied to EWY, which is dominated by SK Hynix and Samsung, and faces bearish technical patterns and seasonally weak August–October trends. Despite EWY's low P/E and high EPS growth, cyclical risks in semiconductors and negative compounding in leveraged ETFs warrant caution.
KORU Medical Systems to Report Second Quarter 2026 Financial Results on August 5, 2026
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report second quarter 2026 financial results on Wednesday, August 5, 2026. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discus.
Why the KORU 3X South Korea Bull ETF Is Surging as SK Hynix Rips on HBM4 News
The Direxion Daily MSCI South Korea Bull 3X Shares (NYSEARCA:KORU) is Tuesday's standout ETF mover, rising roughly 15% intraday as Korean memory chipmakers stage a sharp rebound behind an SK Hynix HBM4 milestone with NVIDIA.
Memory Demand Is Bullish Sign for This Hot ETF
AI's evolution faces several so-called bottlenecks, including constrained supply for memory semiconductors amid booming demand for those chips. For those who want to focus on domestic names with clear ties to that theme, Micron (MU) usually take the cake.
KORU Is Up 236% Year to Date but Just Lost Half Its Value in a Single Trading Day
If you owned Direxion Daily MSCI South Korea Bull 3X Shares (NYSEARCA:KORU) into the close on Friday, June 5, 2026, you watched $10,000 turn into roughly $5,811 in a single session, and you watched a $1,050 share close at $610.
KORU's 274 Percent YTD Gain Looks Stunning Until You See How Fast Daily Resets Can Reverse It
The Direxion Daily MSCI South Korea Bull 3X Shares (NYSEARCA:KORU) is up roughly 274% year to date and a stomach-churning 1,500% over the past twelve months, which is a chart that pulls retail money out of money market funds and into a product most of those buyers do not understand.
KORU Medical Systems Presents Real World Data on the Benefits of the FreedomEDGE Syringe Infusion System in Infusion Clinics at the 51st Annual Oncology Nursing Society Congress
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company presented its latest research at the Oncology Nursing Society (ONS) Congress, May 13-17. The poster at ONS was titled, “Reducing Ergonomic Strain During Subcutaneous Monoclonal Antibody Administration.” The ONS abstract evaluated nur.
KORU: Tuesday's 22% Drop Is A Warning For This 3x Levered South Korea Fund
The South Korean equity market is now heavily concentrated, with Samsung and SK Hynix comprising a large chunk of overall assets. Korea-based funds are behaving increasing like tech/semiconductor ETFs with mounting sector-specific risk. I see 3x leverage as particularly unsuitable for South Korean stocks given the risk of massive volatility in the asset's top holdings.
KORU Medical Systems to Report First Quarter 2026 Financial Results on May 6, 2026
MAHWAH, NJ--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report first quarter 2026 financial results on Wednesday, May 6, 2026. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the.
Magnifying Momentum: Month-to-Date Direxion Inflow Leaders
Today's market uncertainty demands high-conviction trading. With the month of March coming to a close, the latest Direxion leveraged ETF fund flow data reveals a preference for semiconductors, international recovery, and specific high-growth mega-caps.
KORU Medical Secures EU MDR Certification for Freedom60 Infusion Pump
KRMD secures EU MDR certification for its Freedom60 Infusion Pump, opening broader EU access and boosting adoption of patient-friendly home infusion solutions.
Direxion Daily MSCI South Korea Bull 3x Shares (NYSEARCA:KORU) Sees Significant Increase in Short Interest
Direxion Daily MSCI South Korea Bull 3x Shares (NYSEARCA:KORU - Get Free Report) was the target of a large increase in short interest in February. As of February 27th, there was short interest totaling 150,347 shares, an increase of 123.4% from the February 12th total of 67,302 shares. Currently, 11.3% of the company's stock are
KORU Medical Systems Announces EU MDR Certification for the Freedom60® Infusion Pump With Prefilled Syringe Compatibility
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that its Freedom60® Infusion Pump, including adapter for use with 50 mL prefilled syringes, has achieved certification under the European Union Medical Devices Regulation (EU MDR 2017/745), ena.
KORU Medical Systems Announces CEO Transition
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that following five years of service to the Company, Linda Tharby, President and Chief Executive Officer, will retire effective June 30, 2026. The Board of Directors has appointed Adam Kalberma.
KORU Medical Systems Announces +20% Fourth Quarter and Full Year 2025 Revenue Growth, Positive Adjusted EBITDA and Initiates Full Year 2026 Guidance
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. The Company also initiated guidance for the full year 2026. Recent Highlights Fourth quarter 2025 net revenues gre.
3 Reasons This South Korea ETF Is up Over 100% YTD
Volatility continues to rain down on the markets, but there are some shining stars in the bullish leveraged ETF arena. One particular standout is the Direxion Daily South Korea Bull 3X Shares (KORU), which is up over 100% for the year and nearly 400% within the past six months.
A 1,012% One Year Return Could Not Protect KORU From Its Own Structure
A highly-leveraged ETF, Direxion Daily MSCI South Korea Bull 3X ETF ( NYSEARCA:KORU ) dropped 26% in the past week, pulling back from $602.99 to $446.91, even as the fund sits on a staggering 135% gain year-to-date.